SG Americas Securities LLC Buys 26,200 Shares of DaVita Inc. $DVA

SG Americas Securities LLC boosted its stake in DaVita Inc. (NYSE:DVA) by 140.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,844 shares of the company’s stock after acquiring an additional 26,200 shares during the quarter. SG Americas Securities LLC’s holdings in DaVita were worth $5,958,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of DVA. Robeco Institutional Asset Management B.V. boosted its position in DaVita by 11.2% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 49,845 shares of the company’s stock worth $6,623,000 after acquiring an additional 5,036 shares during the last quarter. SJS Investment Consulting Inc. lifted its position in shares of DaVita by 3,091.7% in the third quarter. SJS Investment Consulting Inc. now owns 383 shares of the company’s stock worth $51,000 after purchasing an additional 371 shares in the last quarter. Mather Group LLC. acquired a new position in DaVita during the third quarter worth $119,000. VCI Wealth Management LLC grew its position in DaVita by 52.4% in the third quarter. VCI Wealth Management LLC now owns 7,699 shares of the company’s stock valued at $1,023,000 after purchasing an additional 2,646 shares in the last quarter. Finally, Exchange Traded Concepts LLC increased its stake in DaVita by 83.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 1,660 shares of the company’s stock valued at $221,000 after buying an additional 755 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Price Performance

Shares of DaVita stock opened at $111.43 on Friday. The business has a fifty day simple moving average of $117.66 and a two-hundred day simple moving average of $128.98. DaVita Inc. has a 1 year low of $108.67 and a 1 year high of $179.60. The company has a market capitalization of $7.87 billion, a price-to-earnings ratio of 11.48, a P/E/G ratio of 0.69 and a beta of 0.99.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $3.17 by ($0.66). The company had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.43 billion. DaVita had a net margin of 5.80% and a negative return on equity of 13,370.89%. DaVita’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the previous year, the company earned $2.59 earnings per share. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. As a group, equities analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on DVA shares. Truist Financial reduced their price objective on shares of DaVita from $140.00 to $128.00 and set a “hold” rating for the company in a research note on Monday, January 5th. Cowen reiterated a “hold” rating on shares of DaVita in a report on Monday, November 3rd. TD Cowen decreased their price target on DaVita from $154.00 to $133.00 and set a “hold” rating for the company in a research note on Monday, November 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of DaVita in a research report on Monday, December 29th. Finally, Wall Street Zen downgraded DaVita from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. One equities research analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, DaVita has an average rating of “Hold” and an average target price of $145.60.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.